Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-20
2010-06-08
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S131100
Reexamination Certificate
active
07732400
ABSTRACT:
This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels. The invention also provides a method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to prevent exaggerated restenosis in the subject.
REFERENCES:
patent: 5698531 (1997-12-01), Nabel et al.
patent: 5833651 (1998-11-01), Donovan et al.
patent: 5843102 (1998-12-01), Kalmann et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5879380 (1999-03-01), Kalmann et al.
patent: 6071514 (2000-06-01), Grinell et al.
patent: 6465442 (2002-10-01), Schmidt et al.
patent: 6555340 (2003-04-01), Schmidt et al.
patent: 6555651 (2003-04-01), Stern et al.
patent: 6563015 (2003-05-01), Stern et al.
patent: 6670136 (2003-12-01), Schmidt et al.
patent: 6677299 (2004-01-01), Stern et al.
patent: 6753150 (2004-06-01), Schmidt et al.
patent: 6790443 (2004-09-01), Stern et al.
patent: 6825164 (2004-11-01), Stern et al.
patent: 7026444 (2006-04-01), Schmidt et al.
patent: 7081241 (2006-07-01), Schmidt et al.
patent: 7101838 (2006-09-01), Stern et al.
patent: 7125675 (2006-10-01), Schmidt et al.
patent: 7258857 (2007-08-01), Stern et al.
patent: 2004/0228855 (2004-11-01), Stern et al.
patent: 2005/0129682 (2005-06-01), Schmidt et al.
patent: 2006/0078562 (2006-04-01), Mjalli et al.
patent: 2007/0099829 (2007-05-01), Stern et al.
patent: 2008/0019986 (2008-01-01), Stern et al.
patent: 2008/0207499 (2008-08-01), Barile et al.
patent: WO 97/00857 (1997-07-01), None
patent: WO 97/39121 (1997-10-01), None
patent: WO 97/39125 (1997-10-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO 99/18987 (1999-04-01), None
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
Tomasinsig et al., 2005, Current Protein and Peptide Science, vol. 6, p. 23-34.
Muller et al., 1992, J. Amer. Coll. Cardiol. 19(2):418-432.
Naka et al., 2004, Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, p. 1342-1349.
Park et al., 2001, Circulation, vol. 104, p. 815-819.
Stern et al., U.S. Appl. No. 08/592,070, filed Jan. 26, 1996, including the pending claims.
Allowed claims for U.S. Appl. No. 11/319,949, filed Dec. 27, 2005.
Pending claims for U.S. Appl. No. 09/498,459, a 371 national stage entry of PCT/US98/16303 filed Aug. 5, 1998.
Schmidt et al., U.S. Appl. No. 11/891,680, filed Aug. 9, 2007, including the pending claims.
Pending claims for U.S. Appl. No. 11/584,310, filed Oct. 20, 2006.
Pending claims for U.S. Appl. No. 11/807,884, filed May 29, 2007.
Pending claims for U.S. Appl. No. 11/805,164, filed May 21, 2007.
Stern et al., U.S. Appl. No. 12/009,572, filed Jan. 18, 2008, including the pending claims.
U.S. Appl. No. 09/638,648, filed Aug. 14, 2000, including the pending claims.
U.S. Appl. No. 10/840,927, filed May 7, 2004, including the pending claims.
Pending claims for U.S. Appl. No. 10/990,310, filed Nov. 15, 2004.
Pending claims for U.S. Appl. No. 11/801,635, filed May 9, 2007.
Pending claims for U.S. Appl. No. 11/894,503, filed Aug. 20, 2007.
Ann Marie Schmidt et al., U.S. Appl. No. 10/570,674, a 371 national stage of PCT International Application No. PCT/US04/28712, filed Sep. 3, 2004, including pending claims.
Shi Du Yan et al., U.S. Appl. No. 10/577,506, a 371 national stage of PCT International Application No. PCT/US04/36170, filed Oct. 28, 2004, including pending claims.
Shi Du Yan et al., U.S. Appl. No. 10/577,382, a 371 national stage of PCT International Application No. PCT/US04/36173, filed Oct. 28, 2004, including the pending claims.
Pending claims for U.S. Appl. No. 11/477,274, filed Jun. 28, 2006.
Pending claims for U.S. Appl. No. 11/197,644, filed Aug. 3, 2005.
Pending claims for U.S. Appl. No. 11/630,916, a 371 national stage of PCT International Application No. PCT/US05/27694, filed Aug. 3, 2005.
Pending claims for U.S. Appl. No. 10/850,861, filed May 20, 2004.
Carter et al. (2000) “The Effects of Uncontrolled Hyperglycemia on Thrombosis and Formation of Neointima After Coronary Stent Placement in a Novel Diabetic Porcine Model of Restenosis.”Coronary Artery Disease, 11(6):473-479.
Detre, KM., et al. (2000) “For the BARI Investigators. The Effect of Previous Coronary Artery Bypass Surgery on the Prognosis of Patients With Diabetes Who Have Acute Myocardial Infarction.”N. Engl. J. Med. 342:989-997.
Hofman, MA., et al. (1999) “Rage Mediates A Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides.”Cell97:889-901.
Gu, K., et al. (1999) “Diabetes and The Decline in Heart Disease Mortality in United States Adults.”JAMA281:1291-1297.
Lafont et al. (1998)Card. Res. 39(1):50-59.
Lander, HM. et al., (1997) “Activation of the Receptor for Advanced Glycation Endproducts Triggers a P21ras-Dependent MAP Kinase Pathway Regulated by Oxidant Stress.”J. Biol. Chem., 272:17810-17814.
Muller et al. (1992)J. Amer. Coll. Cardiol. 19(2):418-432.
Naka et al. (2004)Arteriosclerosis, Thrombosis and Vascular Biology. 24:1342-1349.
Neeper, M et al. (1992) “Cloning and Expression of Rage: A Cell Surface Receptor for Advanced Glycation End Products of Proteins.”J. Biol. Chem. 267:14998-15004.
Park, L. et al. (1998) “Suppression of Accelerated Diabetic Atherosclerosis by Soluble Receptor for Age (sRAGE).”Nature Medicine, 4:1025-1031.
Park, SH., et al. (2001) “Neointimal Hyperplasia After Arterial Injury is Increased in a Rat Model of Non-Insulin-Dependent Diabetes Mellitus.”Circulation104:815-819.
Reilly et al. (1993)Drug Dev. Res. 29(2):137-147.
Renard, et al. (1999) “The Human and Rat Recombination Receptors for Advanced Glycation Endproducts Have a High Degree of Homology But Different Pharmacokinetic Properties in Rats.”J. Pharmacology and Experimental Therapeutics, 250 (3):1458-1466.
Rozenman, Y., et al., (1997) “Long-Term Angiographic Follow-Up of Coronary Balloon-Angioplasty in Patients With Diabetes Mellitus: A Clue to the Explanation of the Results of the BARI Study (Balloon Angioplasty Revascularization Investigation).”J. Am. Coll. Cardiol. 30:1420-1425.
Rudinger; (1976) “Characteristics of the Amino Acids As Components of a Peptide Hormone Sequence.”Peptide Hormones: 1-7.
Schmidt AM, et al. (1992) “Isolation and Characterization of Two Binding Proteins for Advanced Glycosylation End Products From Bovine Lung Tissue Which Are Present on the Endothelial Cell Surface.”J. Biol. Chem. 267:14987-14997.
Schmidt, AM, et al. (1994) “Receptor for Advanced Glycation Endproducts (Ages) Has a Central Role in Vessel Wall Interactions and Gene Activation in Response to Circulating AGE Proteins.”PNAS(USA) 91:8807-8811.
Touchard, et al. (2006) “Preclinical Restenosis Models: Challenges and Successes.”Toxicology Pathology, 34;11-18.
Taguchi et al., (2000) “Blockade of RAGE-Amphoterin Signaling Suppresses Tumour Growth and Metastases”Nature, 405-354-360.
Yan, SD., et al. (2000) “Receptor-Dependent Cell Stress and Amyloid Accumulation in Systemic Amyloidosis.”Nat Med. 6:643-51.
Lincoff A. Michael
Marso Steven
Schmidt Ann Marie
Stern David M.
Topol Eric
Chen Shin-Lin
Cooper & Dunham LLP
The Cleveland Clinic Foundation
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Method for inhibiting new tissue growth in blood vessels in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting new tissue growth in blood vessels in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting new tissue growth in blood vessels in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196686